Batna Journal of Medical Sciences
Volume 7, Numéro 2, Pages 71-73
2020-11-09
Authors : Matmour Derouicha .
In mammalian cells, proliferation is controlled by the cell cycle, where cyclin-dependent kinases regulate critical checkpoints. CDK4 is considered a highly validated anticancer drug target due to its essential role in regulating cell cycle progression at the G1 restriction point. Our objective is to design novel CDK4 inhibitors using Structure-Based Drug Design and Quantitative StructureActivity Relationship techniques. We used bioinformatics tools and biological databases. QSAR study of CDK4 inhibitors has given us an idea of the physicochemical features of studied compounds and their correlation with the IC50 activity. The docking study has helped to highlight the molecule key elements to refine in order to get a more potent compound of CDK4. The Molecule under code 21366124 which has the low IC50= 3 nmole shows the most binding affinity with a score value of ΔG=-9,8 kcal/mol. As prospects, it would be very interesting to synthesize this drug candidate and to test its inhibitory activity on the cell culture of breast cancer.
CDK4, Inhibitors, QSAR, SBDD, Docking, Breast cancer.
Sakr Ali
.
Hasegawa-johnson Mark
.
pages 63-71.
Elouar Ibtissem
.
Barhouchi Badra
.
Bouchekioua Saad
.
Aouadi Saoudi
.
pages 37-45.
Bechlem Houria
.
Bougandoura Amina Darine
.
Bahi Meriem
.
Benouchenne Djamila
.
pages 84-97.
Toure Ipétiori Gningayou Laurence Epse Kamara
.
Sessegnon Audrey Fleur
.
Cisse Ibrahima Alhassane
.
Conde Ibrahima Kalil
.
Madiou Mohamed Kassir A
.
Odidi Femi Pérez
.
Agrigna Halourou
.
Kinda Oumar
.
De Akissi Emmanuelle Esther
.
Nogbou Akissi Barbara Marie Yvonne
.
Kouame Norman
.
Toure Sidi
.
Niare Chérif
.
Pacome Gbandama
.
Mebiala Malan Nguessan Prospère
.
Odo Bity Adde
.
Kouassi Kouamé Konan Yvon
.
Toure Moctar
.
pages 12-18.
Kihel Ibtissem
.
Nachi Mourad
.
Entasoltan Badra
.
Bekadja Mohamed Amine
.
pages 555-560.